Evercore ISI Group Maintains In-Line on Sarepta Therapeutics, Raises Price Target to $185
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group has maintained an In-Line rating on Sarepta Therapeutics (NASDAQ:SRPT) and raised the price target from $139 to $185.
June 24, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evercore ISI Group has maintained an In-Line rating on Sarepta Therapeutics and raised the price target from $139 to $185, indicating a positive outlook.
The raised price target from $139 to $185 by Evercore ISI Group suggests a positive outlook for Sarepta Therapeutics. This could lead to increased investor confidence and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100